Posted by Site Administrator on December 29, 2012
In 11 independent studies, a consortium of ALS researchers shows that transplanting neural stem cells into the spinal cord of an ALS mouse model slows disease onset and progression, improves motor function, and significantly prolongs survival.
Categories: Clinical Trials, Research News, Treatments
| 
Tags: ALS, ALS community, ALS medical care, ALS mouse model, ALS research, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, Brigham and Women's Hospital, Evan Y. Snyder, Lou Gehrig's disease, neural stem cells, PALS, Phase II clinical trial, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, Sanford-Burnham Medical Research Institute, Sanford-Burnham Stem Cell and Regenerative Biology Program, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, University of Massachusetts Medical School
| 
No comments
Posted by Site Administrator on December 10, 2012
While some progress has been made in the treatment of ALS, combination therapies with drugs that target other pathways, alongside stem cell technology, are sorely needed
Categories: Clinical Trials, Research News, Treatments
| Tags: 20th International Symposium on ALS/MND, 501(c)(3) ALS charity, AAD 2004, Adult stem cells, ALS, ALS community, ALS medical care, ALS research, ALS treatments, ALSFRS-R, AmKor Pharma, amyotrophic lateral sclerosis, anti-inflammatory effects ALS, antioxidative effects ALS, Arimoclomol, Aß plaque, Bensimon, Biogen Idec, Biorex, Bob Stehlin, Brainstorm, BrainStorm Cell Therapeutics, Cell replacement therapies, dexpramipexole, dopamine receptor, Edaravone, Edaravone IV injection, EMPOWER, fast-track status, FDA, FDA fast-track designation, GNDF-producing adult stem cell therapy, GNT Pharma, Hadassah Medical Center, Hadassah Medical Center Israel, hydroxylamine derivative, inhibition and reduction of beta-amyloid (Aß) peptide levels, Knopp Biosciences, lipoperoxide 15-HPETE, Lou Gehrig's disease, Mitsubishi Tanabe Pharma, NCT01281189, NCT01492686, Neuralstem, neuroprotection, NSI 566RSC, NurOwn, Orphazyme ApS, PALS, Phase I trial, Phase II clinical trial, Phase III trial, PNA Center for Neurological Research, pramipexole, Radicut, RASCALS Foundation, Revised ALS Functional Rating Scale, Rilutek, riluzole, Robert A. Stehlin Campaign for ALS, Sanofi, SOD1, Spinal Cord Delivery Platform and Floating Cannula, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, stem cells, Synthetic Biologics, TCA Cellular Therapy, Tel Aviv University, University of Miami
| No comments
Posted by Site Administrator on November 10, 2012
“Patients who suffer from this devastating disease are in critical need of a novel therapy that addresses the functional deficits that limit their activities of daily living,” stated Jeremy M. Shefner, MD, PhD, Professor and Chair of the Department of Neurology at the Upstate Medical University at the State University of New York and Principal Investigator of BENEFIT-ALS. “If successful, this novel mechanism therapy could improve the lives of many patients living with ALS.”
Categories: Clinical Trials, Research News, Treatments
| Tags: ALS, ALS community, ALS medical care, ALS research, ALS treatments, amyotrophic lateral sclerosis, BENEFIT-ALS (Blinded Evaluation of Neuromusclar Effects and Functional Improvement with Tirasemtiv in ALS), Bob Stehlin, CK-2017357, CY 4026, Cytokinetics Incorporated, Department of Neurology at the Upstate Medical University at the State University of New York, FDA ALS, Jeremy M. Shefner MD PhD, Lou Gehrig's disease, Phase II clinical trial, Phase IIb, RASCALS Foundation, riluzole, Robert A. Stehlin Campaign for ALS, skeletal muscle troponin complex, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, State University of New York, Tirasemtiv
| No comments
Posted by Site Administrator on November 2, 2012
“That is a type of therapy that will apply broadly to all ALS. All of the data would suggest that if ALS is caused by a particular gene, and you shut down that gene, that you should stop the progression of ALS,” Dr. Miller says.
Categories: Clinical Trials, Research News, Treatments
| Tags: ALS, ALS breakthrough, ALS community, ALS fundraiser, ALS research, ALS research funding, ALS treatments, amyotrophic lateral sclerosis, antisense oligonucleotides, Bob Stehlin, Christopher Wells Hobler Laboratory for ALS Research, Dr. Timothy Miller, Dr. Timothy Miller Director of the Christopher Wells Hobler Laboratory for ALS Research, familial ALS, Gandhi Center, genetic ALS, Hope Center for Neurological Disorders at Washington University, Lou Gehrig's disease, PALS, Phase I trial, Phase II clinical trial, RASCALS Foundation, RNA ALS, sporadic ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Washington University St. Louis
| No comments
Posted by Site Administrator on February 20, 2012
With regard to the development of an efficacious treatment for ALS, we are still in its infancy. There is much more to be done—and much more quickly than we’ve seen.
Categories: Research News
| Tags: ALS, ALS community, ALS research, ALS TDI, ALS Therapy Development Institute, clinical trial, compassionate access, Director of Neurology Clinical Trials Unit, FDA, fingolimod, Gilenya, Lou Gehrig’s disease, Massachusetts General Hospital, Merit Cudkowicz Director of Neurology Clinical Trials Unit, Merit Cudkowicz M.D., NEALS, Northeast ALS Consortium, off-label, Phase II clinical trial, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, SOD1 mouse model, St.Louis RASCALS ALS Lou Gehrig’s Disease amotrophic lateral sclerosis, Steve Perrin, TDI 132
| No comments
Posted by Site Administrator on February 19, 2012
Many patients with Lou Gehrig’s disease, a fatal disorder formally known as amyotrophic lateral sclerosis, may want to try the drug on their own—even though there’s no evidence that it is safe or effective in patients with the disease.
Categories: Research News
| Tags: ALS, ALS community, ALS research, ALS TDI, ALS Therapy Development Institute, clinical trial, Director of Neurology Clinical Trials Unit, fingolimod, Gilenya, Lou Gehrig’s disease, Massachusetts General Hospital, Merit Cudkowicz Director of Neurology Clinical Trials Unit, Merit Cudkowicz M.D., NEALS, Northeast ALS Consortium, Phase II clinical trial, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, SOD1 mouse model, St.Louis RASCALS ALS Lou Gehrig’s Disease amotrophic lateral sclerosis, Steve Perrin, TDI 132
| No comments
Posted by Site Administrator on February 14, 2012
The ALS Therapy Development Institute (ALS TDI) will launch a Phase II clinical trial on TDI 132 (aka:fingolimod/Gilenya®) as a potential treatment for ALS (Lou Gehrig’s disease).
Categories: Research News
| Tags: ALS, ALS community, ALS research, ALS TDI, ALS Therapy Development Institute, clinical trial, Director of Neurology Clinical Trials Unit, fingolimod, Gilenya, Lou Gehrig's disease, Massachusetts General Hospital, Merit Cudkowicz Director of Neurology Clinical Trials Unit, Merit Cudkowicz M.D., NEALS, Northeast ALS Consortium, Phase II clinical trial, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, SOD1 mouse model, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Steve Perrin, TDI 132
| No comments
